300562 Guangdong Transtek Medical Electronics
- 9.65
- -0.05-0.52%
Guangdong Transtek Medical Electronics News
Happy Healthcare (300562.SZ): The medical device registration certificate for electronic blood pressure monitors has been approved by Health Canada
Lexin Healthcare (300562.SZ) issued an announcement. The company recently received an equipment license from Health Canada's Medical Devices Department...
Lexin Healthcare (300562.SZ): Has cumulatively repurchased 0.71% of shares
Gelonghui, May 7, 丨 Lexin Healthcare (300562.SZ) announced that as of April 30, 2024, the company had repurchased a total of 1,543,500 shares of the company through centralized bidding through a special securities repurchase account, accounting for 0.71% of the company's current total share capital (the company's current total share capital is 216,901,188 shares). From the initial repurchase to April 30, 2024, the highest transaction price for the company to repurchase shares was 9.66 yuan/share, the lowest transaction price was 6.05 yuan/share, and the total amount paid was 12,819,754.00 yuan (excluding transaction fees).
Lexin Medical (300562.SZ) obtained a medical device registration certificate
Lexin Healthcare (300562.SZ) announced that the company recently received a response from the US FDA and learned that the company is in the US F...
Express News | Happy Healthcare: Electronic blood pressure monitor medical device registration has been approved by the US FDA
Happy Healthcare (300562): 1Q24 gross margin increased by 9.61 PCT year on year and returned to a healthy growth trajectory
1Q24 revenue increased 53% year over year, and the company returned to a healthy growth trajectory. 1Q24 achieved revenue of 249 million yuan (YoY +52.93%, QoQ -9.90%) and net profit of 14 million yuan to mother
Happy Healthcare (300562): 1Q24 profitability optimization is optimistic about steady revenue growth in 2024
1Q24 profitability optimization, optimistic about steady revenue growth in 2024, Happy Healthcare's 1Q24 revenue of 249 million yuan (YoY: 52.9%; QoQ: -10.0%), net profit to mother of 214 million yuan (
Happy Healthcare (300562): Outstanding performance in 2024Q1, strategic upgrade was very effective
Incident: 1) On April 24, the company released its 2024 quarterly report. 2024Q1 achieved operating income of 249 million yuan (yoy +52.93%) and net profit of 14 million yuan (yoy)
Lexin Healthcare (300562.SZ): Net profit of 136.656 million yuan for the first quarter reversed the year-on-year loss
On April 24, Gelonghui Medical (300562.SZ) released its first quarter report. Operating revenue was 249 million yuan, up 52.93% year on year, net profit of 136.656 million yuan, reversed year-on-year losses, after deducting non-net profit of 11.916,600 yuan, reversing year-on-year losses, with basic earnings of 0.06 yuan per share.
Lexin Healthcare (300562.SZ) plans to distribute 10 shares of 1.51,075 yuan to be deducted from interest on April 25
Lexin Healthcare (300562.SZ) announced that the company's 2023 equity distribution plan: to all shareholders for every 10...
Happy Healthcare (300562.SZ): Proposed 2024 Employee Stock Ownership Plan
Gelonghui, April 10 | Lexin Healthcare (300562.SZ) announced the 2024 employee stock ownership plan. The number of underlying shares to be held by the employee's shareholding plan is no more than 1.50 million shares, accounting for 0.69% of the company's total share capital of 216.90.118 million shares on the day the draft employee shareholding plan was announced. The maximum amount of capital to be raised in the employee stock ownership plan is 6.87 million yuan. Using “shares” as the subscription unit, each share is 1.00 yuan. The price of the employee's shareholding plan to buy back shares is 4.58 yuan/share.
Happy Healthcare (300562.SZ): The application for a medical device registration certificate was accepted
Gelonghui, April 7 | Lexin Healthcare (300562.SZ) announced that it recently received a response from Health Canada's Medical Devices Division Equipment Licensing Service Division and learned that the company's application for registration of an electronic blood pressure monitor medical device has been accepted.
Happy Healthcare (300562): High net profit growth, in-depth layout of telemedicine “AI+IOT”
Incident: On March 25, the company released its 2023 annual report. In 2023, the company achieved operating income of 884 million yuan (-16.98%) and net profit to mother of 34 million yuan (+206.21%)
Lexin Healthcare (300562.SZ): 0.60% of shares have been repurchased
Gelonghui, April 1, 丨 Lexin Medical (300562.SZ) announced that as of March 31, 2024, the company had repurchased a total of 1,311,600 shares of the company through centralized bidding through a special securities repurchase account, accounting for 0.60% of the company's current total share capital (the company's current total share capital is 216,901,188 shares). From the initial repurchase until March 31, 2024, the highest transaction price for the company to repurchase shares was 9.66 yuan/share, the lowest transaction price was 6.05 yuan/share, and the total amount paid was 10,759,801.00 yuan (excluding transaction fees).
Happy Healthcare (300562.SZ): The application for registration of the electronic blood pressure monitor medical device 510 (k) has been accepted
On March 27, Ge Longhui Medical (300562.SZ) announced that the company recently received the “Complication Letter” from the US FDA and learned that the 510 (k) registration application for an electronic blood pressure monitor medical device declared by the company has been accepted.
Happy Healthcare (300562): Annual profit increased year-on-year, optimistic about overseas expansion/AI+ medical trends
Net profit to mother increased year-on-year. Optimistic about overseas RPM expansion in 24 years and benefiting from AI+ Healthcare, Lexin Medical achieved revenue of 800 million yuan (YoY: -16.98%) in 2023, and net profit to mother 3,436.73
Lexin Healthcare (300562): Medical grade remote health monitoring equipment and service provider
A provider of medical grade remote health monitoring equipment and services, turning losses into profits in 23 years. Since its establishment in 2000, the company's product matrix has been continuously enriched, and the strategic positioning has gradually become clear. From the past, the three traditional categories (scales+wearable products+blood
Lexin Healthcare (300562.SZ): Net profit of 34.3673 million yuan in 2023, plans to pay 10 to 1.5 yuan
Gelonghui, March 25 | Lexin Healthcare (300562.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 884 million yuan, a year-on-year decrease of 16.98%; net profit attributable to shareholders of listed companies was 34,3673 million yuan, turning a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of 225.392 million yuan; basic earnings per share of 0.1597 yuan; plans to distribute a cash dividend of 1.50 yuan (tax included) for every 10 shares to all shareholders
Express News | Happy Healthcare: The application for registration of an upper arm electronic blood pressure monitor medical device has been accepted
Lexin Healthcare (300562.SZ): Initial repurchase of 260,000 shares
Gelonghui, Feb. 6 | Lexin Healthcare (300562.SZ) announced that on February 6, 2024, the company repurchased 260,000 shares of the company's shares through a dedicated securities account through centralized bidding, accounting for 0.12% of the company's current total share capital (the company's current total share capital is 216,901,188 shares). The highest transaction price for the initial repurchase was 7.16 yuan/share, the lowest transaction price was 6.41 yuan/share, and the total amount paid was 1,722,544 yuan.
Lexin Healthcare (300562.SZ): Plans to spend 20 million yuan to 40 million yuan to buy back the company's shares
Gelonghui, Feb. 1 | Happy Healthcare (300562.SZ) announced that the company plans to use its own funds to repurchase RMB common shares (A shares) issued by the company through centralized bidding for share incentives or employee shareholding plans. The total amount of shares to be repurchased is not less than RMB 20 million (including the number of shares) and not more than RMB 40 million (including the number of shares); the repurchase price is not higher than RMB 16.00 per share (inclusive). Based on the maximum proposed repurchase price of 16.00 yuan/share (inclusive) and the lower limit of the total amount to be used to repurchase shares of 20 million yuan (inclusive), the number of shares to be repurchased is approximately 12
Analysis
Price Target
No Data
